Inhibiting C-reactive protein for the treatment of cardiovascular disease: Promising evidence from rodent models

Mediators of Inflammation

Volumn 2014, Issue , 2014, Pages

  Szalai, Alexander J ^a   McCrory, Mark A ^a   Xing, Dongqi ^b   Hage, Fadi G ^b   Miller, Andrew ^b   Oparil, Suzanne ^b   Chen, Yiu Fai ^b   Mazzone, Michelle ^c   Early, Richard ^c   Henry, Scott P ^d   Zanardi, Thomas A ^d   Graham, Mark J ^d   Crooke, Rosanne M ^d  

^a The University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c CHARLES RIVER LABORATORIES   (United States)

^d ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; C REACTIVE PROTEIN;

ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CARDIOVASCULAR DISEASES; ECHOCARDIOGRAPHY; FEMALE; MALE; METABOLISM; MOUSE; MYOCARDIAL INFARCTION; RAT; SPRAGUE DAWLEY RAT;

ANIMALS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; ECHOCARDIOGRAPHY; FEMALE; MALE; MICE; MYOCARDIAL INFARCTION; OLIGONUCLEOTIDES, ANTISENSE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84899459109     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2014/353614     Document Type: Article

References (48)

1. Yeh E. T. H., A new perspective on the biology of C-reactive protein. Circulation Research 2005 97 7 609 611 2-s2.0-26244450390 10.1161/01.RES. 0000186188.38344.13 (Pubitemid 41416327)
2. Verma S., Szmitko P. E., Ridker P. M., C-reactive protein comes of age. Nature Clinical Practice Cardiovascular Medicine 2005 2 1 29 36 2-s2.0-20444435997 10.1038/ncpcardio0074 (Pubitemid 40823207)
3. Black S., Kushner I., Samols D., C-reactive protein. Journal of Biological Chemistry 2004 279 47 48487 48490 2-s2.0-10344239447 10.1074/jbc.R400025200 (Pubitemid 39625721)
4. Du Clos T. W., Pentraxins: structure, function, and role in inflammation. ISRN Inflammation 2013 2013 22 379040 10.1155/2013/379040
5. Kushner I., Jiang S.-L., Zhang D., Lozanski G., Samols D., Do post-transcriptional mechanisms participate in induction of C-reactive protein and serum amyloid A by IL-6 and IL-1? Annals of the New York Academy of Sciences 1995 762 102 107 2-s2.0-0029146340
6. Kushner I., Rzewnicki D., Samols D., What does minor elevation of C-reactive protein signify? American Journal of Medicine 2006 119 2 166.e17 166.e28 2-s2.0-31444437678 10.1016/j.amjmed.2005.06.057 (Pubitemid 43151486)
7. Pradhan A. D., Manson J. E., Rifai N., Buring J. E., Ridker P. M., C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. Journal of the American Medical Association 2001 286 3 327 334 2-s2.0-0035908632 (Pubitemid 32656163)
8. Laaksonen D. E., Niskanen L., Nyyssönen K., Punnonen K., Tuomainen T.-P., Valkonen V.-P., Salonen R., Salonen J. T., C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men. Diabetologia 2004 47 8 1402 1410 2-s2.0-16644382305 10.1007/s00125-004-1472-x (Pubitemid 39232426)
9. Haffner S. M., The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. American Journal of Cardiology 2006 97 2 3A 11A 2-s2.0-31344447948 10.1016/j.amjcard.2005.11.010 (Pubitemid 43139714)
10. Hage F. G., Szalai A. J., C-reactive protein gene polymorphisms, C-reactive protein nlood levels, and cardiovascular disease risk. Journal of the American College of Cardiology 2007 50 12 1115 1122 2-s2.0-34548484599 10.1016/j.jacc.2007.06.012 (Pubitemid 47375011)
11. Nissen S. E., Tuzcu E. M., Schoenhagen P., Crowe T., Sasiela W. J., Tsai J., Orazem J., Magorien R. D., O'Shaughnessy C., Ganz P., Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. The New England Journal of Medicine 2005 352 1 29 38 2-s2.0-19944429519 10.1056/NEJMoa042000 (Pubitemid 40075678)
12. Ridker P. M., Cannon C. P., Morrow D., Rifai N., Rose L. M., McCabe C. H., Pfeffer M. A., Braunwald E., C-reactive protein levels and outcomes after statin therapy. The New England Journal of Medicine 2005 352 1 20 28 2-s2.0-11344279659 10.1056/NEJMoa042378 (Pubitemid 40075677)
13. Ridker P. M., Danielson E., Fonseca F. A. H., Genest J., Gotto A. M. Jr., Kastelein J. J. P., Koenig W., Libby P., Lorenzatti A. J., MacFadyen J. G., Nordestgaard B. G., Shepherd J., Willerson J. T., Glynn R. J., Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. The New England Journal of Medicine 2008 359 21 2195 2207 2-s2.0-56749106312 10.1056/NEJMoa0807646
14. Puri R., Nissen S. E., Libby P., Shao M., Ballantyne C. M., Barter P. J., Chapman M. J., Erbel R., Raichlen J. S., Uno K., Kataoka Y., Nicholls S. J., C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy. Circulation 2013 128 22 2395 2403 10.1161/CIRCULATIONAHA.113.004243
15. Verma S., Devaraj S., Jialal I., C-reactive protein promotes atherothrombosis. Circulation 2006 113 17 2135 2150 2-s2.0-33646439567
16. Wolbink G. J., Brouwer M. C., Buysmann S., Berge I. J. M. T., Hack C. E., CRP-mediated activation of complement in vivo: assessment by measuring circulating complement-C-reactive protein complexes. Journal of Immunology 1996 157 1 473 479 2-s2.0-0029927303 (Pubitemid 26190582)
17. Sun H., Koike T., Ichikawa T., Hatakeyama K., Shiomi M., Zhang B., Kitajima S., Morimoto M., Watanabe T., Asada Y., Chen Y. E., Fan J., C-reactive protein in atherosclerotic lesions: its origin and pathophysiological significance. American Journal of Pathology 2005 167 4 1139 1148 2-s2.0-26244461959 (Pubitemid 41416264)
18. Torzewski J., Torzewski M., Bowyer D. E., Fröhlich M., Koenig W., Waltenberger J., Fitzsimmons C., Hombach V., C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arteriosclerosis, Thrombosis, and Vascular Biology 1998 18 9 1386 1392 2-s2.0-0031668698 (Pubitemid 28421875)
19. Meuwissen M., van der Wal A. C., Niessen H. W. M., Koch K. T., de Winter R. J., van der Loos C. M., Rittersma S. Z. H., Chamuleau S. A. J., Tijssen J. G. P., Becker A. E., Piek J. J., Colocalisation of intraplaque C reactive protein, complement, oxidised low density lipoprotein, and macrophages in stable and unstable angina and acute myocardial infarction. Journal of Clinical Pathology 2006 59 2 196 201 2-s2.0-32544448716 10.1136/jcp.2005.027235 (Pubitemid 43235587)
20. Ji S.-R., Wu Y., Potempa L. A., Liang Y.-H., Zhao J., Effect of modified C-reactive protein on complement activation: a possible complement regulatory role of modified or monomeric C-reactive protein in atherosclerotic lesions. Arteriosclerosis, Thrombosis, and Vascular Biology 2006 26 4 934 941 2-s2.0-33646681859 10.1161/01.ATV.0000206211.21895.73 (Pubitemid 43732175)
21. Bhakdi S., Torzewski M., Klouche M., Hemmes M., Complement and atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances complement activation. Arteriosclerosis, Thrombosis, and Vascular Biology 1999 19 10 2348 2354 2-s2.0-0032851173 (Pubitemid 29477835)
22. Danenberg H. D., Szalai A. J., Swaminathan R. V., Peng L., Chen Z., Seifert P., Fay W. P., Simon D. I., Edelman E. R., Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice. Circulation 2003 108 5 512 515 2-s2.0-0043075885 10.1161/01.CIR.0000085568.13915.1E (Pubitemid 36961161)
23. Paul A., Ko K. W. S., Li L., Yechoor V., McCrory M. A., Szalai A. J., Chan L., C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation 2004 109 5 647 655 2-s2.0-1042301971 10.1161/01.CIR.0000114526.50618.24 (Pubitemid 38198873)
24. Wang D., Oparil S., Chen Y.-F., McCrory M. A., Skibinski G. A., Feng W., Szalai A. J., Estrogen treatment abrogates neointima formation in human C-reactive protein transgenic mice. Arteriosclerosis, Thrombosis, and Vascular Biology 2005 25 10 2094 2099 2-s2.0-26244458381 10.1161/01.ATV.0000179602.85797. 3f (Pubitemid 41416306)
25. Xing D., Hage F. G., Chen Y.-F., McCrory M. A., Feng W., Skibinski G. A., Majid-Hassan E., Oparil S., Szalai A. J., Exaggerated neointima formation in human C-reactive protein transgenic mice is IgG Fc receptor type I (Fc γ RI)-dependent. American Journal of Pathology 2008 172 1 22 30 2-s2.0-38749085282 10.2353/ajpath.2008.070154 (Pubitemid 351186364)
26. Hingorani A. D., Shah T., Casas J. P., Linking observational and genetic approaches to determine the role of C-reactive protein in heart disease risk. European Heart Journal 2006 27 11 1261 1263 2-s2.0-33745683664 10.1093/eurheartj/ehi852 (Pubitemid 43998093)
27. Pepys M. B., Hirschfield G. M., Tennent G. A., Gallimore J. R., Kahan M. C., Bellotti V., Hawkins P. N., Myers R. M., Smith M. D., Polara A., Cobb A. J. A., Ley S. V., Aquilina J. A., Robinson C. V., Sharif I., Gray G. A., Sabin C. A., Jenvey M. C., Kolstoe S. E., Thompson D., Wood S. P., Targeting C-reactive protein for the treatment of cardiovascular disease. Nature 2006 440 7088 1217 1221 2-s2.0-33646366683 10.1038/nature04672
28. Crooke S. T., Progress in antisense technology. Annual Review of Medicine 2004 55 61 95 2-s2.0-1542269161 10.1146/annurev.med.55.091902.104408 (Pubitemid 38316716)
29. Szalai A. J., McCrory M. A., Varied biologic functions of C-reactive protein: lessons learned from transgenic mice. Immunologic Research 2002 26 1-3 279 287 2-s2.0-0036397602 10.1385/IR:26:1-3:279 (Pubitemid 35177504)
30. Murphy C., Beckers J., Ruther U., Regulation of the human C-reactive protein gene in transgenic mice. Journal of Biological Chemistry 1995 270 2 704 708 2-s2.0-0028954550 10.1074/jbc.270.2.704
31. Jones N. R., Pegues M. A., McCrory M. A., Singleton W., Bethune C., Baker B. F., Norris D. A., Crooke R. M., Graham M. J., Szalai A. J., A selective inhibitor of human C-reactive protein translation is efficacious in vitro and in C-reactive protein transgenic mice and humans. Molecular therapy: Nucleic acids 2012 1, article e52
32. Crooke R. M., Graham M. J., Lemonidis K. M., Whipple C. P., Koo S., Perera R. J., An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis. Journal of Lipid Research 2005 46 5 872 884 2-s2.0-20544474017 10.1194/jlr.M400492-JLR200
33. Zhao X., Zhang W., Xing D., Li P., Fu J., Gong K., Hage F. G., Oparil S., Chen Y. F., Endothelial cells overexpressing IL-8 receptor reduce cardiac remodeling and dysfunction following myocardial infarction. American Journal of Physiology: Heart and Circulatory Physiology 2013 305 4 H590 H598 10.1152/ajpheart.00571.2012
34. Castell J. V., Andus T., Kunz D., Heinrich P. C., Interleukin-6: the major regulator of acute-phase protein synthesis in man and rat. Annals of the New York Academy of Sciences 1989 557 87 101 2-s2.0-0024323353 (Pubitemid 19210817)
35. Scirica B. M., Morrow D. A., Verma S., Jialal I., The verdict is still out. Circulation 2006 113 17 2128 2134 2-s2.0-33646458544 10.1161/ CIRCULATIONAHA.105.611350
36. Ablij H. C., Meinders A. E., C-reactive protein: history and revival. European Journal of Internal Medicine 2002 13 7 412 422 2-s2.0-0036792245 10.1016/S0953-6205(02)00132-2
37. Jialal I., Devaraj S., Venugopal S. K., C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension 2004 44 1 6 11 2-s2.0-3042677716 10.1161/01.HYP.0000130484.20501.df (Pubitemid 38823477)
38. Olofsson S.-O., Boren J., Apolipoprotein B: a clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosis. Journal of Internal Medicine 2005 258 5 395 410 2-s2.0-27544438601 10.1111/j.1365-2796.2005.01556.x (Pubitemid 41546555)
39. Kastelein J. J. P., Wedel M. K., Baker B. F., Su J., Bradley J. D., Yu R. Z., Chuang E., Graham M. J., Crooke R. M., Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 2006 114 16 1729 1735 2-s2.0-33750207033 10.1161/CIRCULATIONAHA.105.606442 (Pubitemid 44607121)
40. Akdim F., Stroes E. S. G., Kastelein J. J. P., Antisense apolipoprotein B therapy: where do we stand? Current Opinion in Lipidology 2007 18 4 397 400 2-s2.0-34447300969 10.1097/MOL.0b013e328248b4ad (Pubitemid 47051917)
41. Kwoh T. J., Crooke S. T., An overview of the clinical safety experience of first- and second- generation antisense oligonucleotides. Antisense Drug Technology: Principles, Strategies and Applications 2008 2nd Boca Raton, Fla, USA CRC Press 299 365
42. Geary R. S., Yu R. Z., Siwkowski A., Levin A. A., Crooke S. T., Pharmacokinetic properties of phosphorothioate 2′-O-(2-methoxyethyl)- modified antisense oligonucleotides in animals and man. Antisense Drug Technology: Principles, Strategies and Applications 2008 2nd Boca Raton, Fla, USA CRC Press 305 326
43. Yu R. Z., Kim T.-W., Hong A., Watanabe T. A., Gaus H. J., Geary R. S., Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100. Drug Metabolism and Disposition 2007 35 3 460 468 2-s2.0-33847338002 10.1124/dmd.106.012401 (Pubitemid 46333910)
44. Graham M. J., Crooke S. T., Lemonidis K. M., Gaus H. J., Templin M. V., Crooke R. M., Hepatic distribution of a phosphorothioate oligodeoxynucleotide within rodents following intravenous administration. Biochemical Pharmacology 2001 62 3 297 306 2-s2.0-0035427644 10.1016/S0006-2952(01)00669-4 (Pubitemid 32575330)
45. Hage F. G., Oparil S., Xing D., Chen Y.-F., McCrory M. A., Szalai A. J., C-reactive protein-mediated vascular injury requires complement. Arteriosclerosis, Thrombosis, and Vascular Biology 2010 30 6 1189 1195 2-s2.0-77952823994 10.1161/ATVBAHA.110.205377
46. Wilson A. M., Ryan M. C., Boyle A. J., The novel role of C-reactive protein in cardiovascular disease: risk marker or pathogen. International Journal of Cardiology 2006 106 3 291 297 2-s2.0-28844475044 10.1016/j.ijcard. 2005.01.068 (Pubitemid 41766629)
47. de Ferranti S. D., Rifai N., C-reactive protein: a nontraditional serum marker of cardiovascular risk. Cardiovascular Pathology 2007 16 1 14 21 2-s2.0-33845980607 10.1016/j.carpath.2006.04.006 (Pubitemid 46049026)
48. Biasucci L. M., CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: clinical use of inflammatory markers in patients with cardiovascular diseases: a background paper. Circulation 2004 110 25 e560 e567 2-s2.0-26244438799